JP2021523096A5 - - Google Patents
Info
- Publication number
- JP2021523096A5 JP2021523096A5 JP2020556807A JP2020556807A JP2021523096A5 JP 2021523096 A5 JP2021523096 A5 JP 2021523096A5 JP 2020556807 A JP2020556807 A JP 2020556807A JP 2020556807 A JP2020556807 A JP 2020556807A JP 2021523096 A5 JP2021523096 A5 JP 2021523096A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- pharmaceutical composition
- composition according
- protein
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671963P | 2018-05-15 | 2018-05-15 | |
| US62/671,963 | 2018-05-15 | ||
| US201962804931P | 2019-02-13 | 2019-02-13 | |
| US62/804,931 | 2019-02-13 | ||
| PCT/US2019/032271 WO2019222252A1 (en) | 2018-05-15 | 2019-05-14 | Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523096A JP2021523096A (ja) | 2021-09-02 |
| JP2021523096A5 true JP2021523096A5 (enExample) | 2022-05-18 |
Family
ID=68540945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556807A Pending JP2021523096A (ja) | 2018-05-15 | 2019-05-14 | 未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210061899A1 (enExample) |
| EP (1) | EP3813868A4 (enExample) |
| JP (1) | JP2021523096A (enExample) |
| KR (1) | KR20210009339A (enExample) |
| CN (1) | CN112118858A (enExample) |
| AU (1) | AU2019271065A1 (enExample) |
| BR (1) | BR112020021082A2 (enExample) |
| CA (1) | CA3096844A1 (enExample) |
| MX (1) | MX2020011638A (enExample) |
| SG (1) | SG11202011148VA (enExample) |
| TW (1) | TW202003577A (enExample) |
| WO (1) | WO2019222252A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3158047A1 (en) * | 2019-12-11 | 2021-06-17 | Yunying CHEN | Bi-functional antibody against pd-l1 and tgf? |
| WO2021218883A1 (zh) * | 2020-04-28 | 2021-11-04 | 神州细胞工程有限公司 | 一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途 |
| EP4194002A4 (en) * | 2020-07-24 | 2024-08-14 | Mabwell (Shanghai) Bioscience Co., Ltd. | TGF-BETA RII MUTANT AND ASSOCIATED FUSION PROTEIN |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201216649D0 (en) * | 2012-09-18 | 2012-10-31 | Univ Birmingham | Agents and methods |
| MY186864A (en) * | 2013-03-12 | 2021-08-26 | Biocon Ltd | Fusion immunomodulatory proteins and methods for making same |
| HRP20210977T1 (hr) * | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| SG10201913538VA (en) * | 2015-11-23 | 2020-02-27 | Five Prime Therapeutics Inc | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
| JP7573365B2 (ja) * | 2016-08-12 | 2024-10-25 | メルク パテント ゲーエムベーハー | 癌の併用療法 |
-
2019
- 2019-05-14 BR BR112020021082-0A patent/BR112020021082A2/pt not_active Application Discontinuation
- 2019-05-14 KR KR1020207035552A patent/KR20210009339A/ko not_active Withdrawn
- 2019-05-14 AU AU2019271065A patent/AU2019271065A1/en not_active Abandoned
- 2019-05-14 CN CN201980032533.9A patent/CN112118858A/zh active Pending
- 2019-05-14 SG SG11202011148VA patent/SG11202011148VA/en unknown
- 2019-05-14 MX MX2020011638A patent/MX2020011638A/es unknown
- 2019-05-14 CA CA3096844A patent/CA3096844A1/en active Pending
- 2019-05-14 WO PCT/US2019/032271 patent/WO2019222252A1/en not_active Ceased
- 2019-05-14 EP EP19804320.0A patent/EP3813868A4/en not_active Withdrawn
- 2019-05-14 JP JP2020556807A patent/JP2021523096A/ja active Pending
- 2019-05-15 TW TW108116801A patent/TW202003577A/zh unknown
-
2020
- 2020-11-11 US US17/095,377 patent/US20210061899A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| JP2019517549A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| RU2679119C2 (ru) | Лечение неопластических заболеваний | |
| JP2021534094A5 (enExample) | ||
| JP2021527083A5 (enExample) | ||
| JP2020510039A5 (enExample) | ||
| WO2022052874A1 (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| JP2014500278A (ja) | 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与 | |
| CN114423453A (zh) | 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit) | |
| WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| JP2021529777A5 (enExample) | ||
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| JP2021528399A5 (enExample) | ||
| JP2024542777A5 (enExample) | ||
| JP2024521105A5 (enExample) | ||
| JP2024511977A5 (enExample) | ||
| JP2024500912A5 (enExample) | ||
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| CN110996991A (zh) | haNK西妥昔单抗组合和方法 | |
| WO2023072043A1 (zh) | 治疗肿瘤的联用药物 | |
| TW202322855A (zh) | 人類表皮生長因子第二型受體疫苗組成物以及套組 | |
| RU2020141021A (ru) | Схемы введения доз для направленного ингибирования tgf-в в целях их применения для лечения рака у индивидуумов, ранее не проходивших лечение |